Mar 25 |
REVB Begins Trials with Good Cash on Hand
|
Mar 22 |
Revelation Biosciences GAAP EPS of -$8.33
|
Mar 22 |
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
|
Mar 13 |
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
|
Mar 12 |
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
|
Mar 4 |
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
|
Feb 13 |
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
|
Feb 9 |
Top 5 Health Care Stocks That Are Preparing To Pump In February
|
Feb 5 |
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
|
Feb 2 |
Why Meta Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
|